MedTrace Logo

Gardasil Immunogenicity With Needle-Free Injection

NCT01924754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-10-13

Study results available
· View outcomes & findings →

Summary

Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to measure the strength of their response to the vaccine.

Conditions

  • HPV Seroconversion

Sponsors & Collaborators

Principal Investigators

  • Joel Palefsky, M.D. · University of California, San Francisco

Eligibility

Min Age
18 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01924754 on ClinicalTrials.gov